Key result
GBCK25 treatment significantly reduced body weights and ameliorated heart function through normalized levels of left ventricle systolic pressure, ejection fraction, and fractional shortening in mice.
Why the study?
Does fermented ginseng (GBCK25) improve cardiac dysfunction in high-fat diet-induced obese mice?
Does fermented ginseng (GBCK25) improve cardiac dysfunction in high-fat diet-induced obese mice?
Fermented ginseng (GBCK25) shows potential as a nutraceutical for alleviating high-fat diet-induced obesity-mediated cardiac dysfunction in a preclinical model.
Answers are grounded in this paper and cite their sources.
Fermented ginseng may benefit metabolic cardiomyopathy models; leaves open human translation pending prospective trials.
The fermentation of medicinal herbs facilitated by microbes is assumed to exert promising therapeutic efficacy on the absorption, bioavailability, and pharmacological effects by speeding up the making or conversion of active constituents into their metabolites. We examined the cardioprotective potential of fermented ginseng, GBCK25, against high-fat diet (HFD)-induced metabolic and functional illnesses as following the essential analysis such as electrocardiographic parameters, alterations of body and organ weights, and echocardiographic studies. The results exhibited that body weights were significantly reduced and the gain of different organ weights were partly eased by GBCK25 treatment. Echocardiography results proposed the amelioration of heart function through normalized levels of left ventricle systolic pressure, ejection fraction, and fractional shortening. These outcomes deliver straight confirmation that GBCK25 could be a potential nutraceutical source for the relief of HFD-induced obesity mediated cardiac dysfunctions.
No takes yet. Share an insight, caveat, or question.
Sharmila et al. (2017) studied High fat diet-induced obesity and cardiac dysfunction. GBCK25 (fermented ginseng) was evaluated on Cardiac dysfunction (electrocardiographic parameters, body/organ weights, echocardiographic studies). GBCK25 treatment significantly reduced body weights and ameliorated heart function through normalized levels of left ventricle systolic pressure, ejection fraction, and fractional shortening in mice.
Synapse has enriched 10 related papers. Consider them for comparative context: